IGF-1 DES (Des(1-3) IGF-1) vs IGF-1 LR3 (Long R3 IGF-1)
Updated September 21, 2026 · Reviewed by the PeptidesDB Editorial team
A data-driven comparison of IGF-1 DES (Des(1-3) IGF-1) and IGF-1 LR3 (Long R3 IGF-1) (also searched as IGF-1 LR3 (Long R3 IGF-1) vs IGF-1 DES (Des(1-3) IGF-1)) — effect profiles, evidence, side effects, and which suits weight loss, muscle, or healing goals.
Verdict
IGF-1 DES (Des(1-3) IGF-1) centers on muscle, while IGF-1 LR3 (Long R3 IGF-1) leans toward muscle. On indexed research, IGF-1 DES (Des(1-3) IGF-1) is ahead (IGF-1 DES (Des(1-3) IGF-1): 22 studies, Human clinical; IGF-1 LR3 (Long R3 IGF-1): 14, Human evidence). Choose by goal — and read the primary studies. This is research information, not medical advice.
Key takeaways
- •IGF-1 DES (Des(1-3) IGF-1) is strongest for muscle; IGF-1 LR3 (Long R3 IGF-1) for muscle.
- •Evidence: IGF-1 DES (Des(1-3) IGF-1) Human clinical (22 studies) vs IGF-1 LR3 (Long R3 IGF-1) Human evidence (14).
- •Both are research-use compounds — not FDA-approved.
Effect profiles, overlaid
At a glance
Localized muscle growth | Tissue repair
IGF-1 receptor agonist | Muscle growth
IGF-1 DES (Des(1-3) IGF-1) vs IGF-1 LR3 (Long R3 IGF-1): side-by-side
| Metric | IGF-1 DES (Des(1-3) IGF-1) | IGF-1 LR3 (Long R3 IGF-1) |
|---|---|---|
| Class | Muscle | Muscle |
| Regulatory status | Research use only | Research use only |
| Evidence grade | Human clinical | Human evidence |
| Studies indexed | 22 | 14 |
| Research level | Moderate Research | Preclinical |
| Strongest effect | Muscle & body comp | Muscle & body comp |
| Healing & recovery | 3.0▲ | 1.0 |
| Muscle & body comp | 5.0▲ | 5.0▲ |
| Metabolic & appetite | 2.0 | 3.0▲ |
| Neuro & mood | 1.0 | 2.0▲ |
| Sleep & circadian | 0.0 | 0.0 |
| Inflammation & immune | 2.0▲ | 1.0 |
| Skin & aesthetics | 3.0▲ | 2.0 |
▲ marks the higher AI-assigned effect score (0–5, describing where the literature concentrates — not clinical efficacy).
Mechanism & pharmacokinetics
| Property | IGF-1 DES (Des(1-3) IGF-1) | IGF-1 LR3 (Long R3 IGF-1) |
|---|---|---|
| Mechanism | IGF-1 receptor agonist | IGF-1 receptor agonist |
| Route | Subcutaneous injection | Subcutaneous injection |
| Half-life | — | ~20-30 hours |
Established pharmacology — curated for well-characterized compounds and AI-summarized otherwise. A blank (—) means no reliable single value is published (half-life figures for some peptides genuinely disagree across sources). Verify against primary sources such as FDA labels and ClinicalTrials.gov.
What is IGF-1 DES (Des(1-3) IGF-1)?
IGF-1 DES (Des(1-3) IGF-1) is a truncated IGF-1 analog studied for localized muscle growth and tissue repair, with reduced IGFBP binding and higher local receptor activity.
Full IGF-1 DES (Des(1-3) IGF-1) profile, mechanism & studies →What is IGF-1 LR3 (Long R3 IGF-1)?
IGF-1 LR3 is a long-acting synthetic IGF-1 analog with reduced binding-protein affinity, used as a research-grade IGF-1 receptor agonist studied for muscle and tissue growth.
Full IGF-1 LR3 (Long R3 IGF-1) profile, mechanism & studies →Which is better for your goal?
| Goal | Better fit | Why |
|---|---|---|
| Healing | IGF-1 DES (Des(1-3) IGF-1) | 3.0/5 effect signal |
| Muscle | Even | Both ~5.0/5 |
| Metabolic | IGF-1 LR3 (Long R3 IGF-1) | 3.0/5 effect signal |
| Neuro | IGF-1 LR3 (Long R3 IGF-1) | 2.0/5 effect signal |
| Inflammation | IGF-1 DES (Des(1-3) IGF-1) | 2.0/5 effect signal |
| Skin | IGF-1 DES (Des(1-3) IGF-1) | 3.0/5 effect signal |
Fit reflects community-perceived effect profiles — not head-to-head trials. Read each peptide's studies before deciding.
Can you stack IGF-1 DES (Des(1-3) IGF-1) and IGF-1 LR3 (Long R3 IGF-1)?
People sometimes combine peptides that target different pathways, but there is little controlled research on this specific pairing and the interactions aren't well characterized. Because neither compound is FDA-approved, we don't publish stacking or dosing protocols here. Any combination should be discussed with a qualified clinician.
IGF-1 DES (Des(1-3) IGF-1) vs IGF-1 LR3 (Long R3 IGF-1): side effects
No community-reported effects logged yet.
No community-reported effects logged yet.
Anonymous community reports (count = number of reports), not clinical incidence rates.
What the research says
IGF-1 DES (Des(1-3) IGF-1) has 22 approved studies indexed (Human clinical), and IGF-1 LR3 (Long R3 IGF-1) has 14 (Human evidence). The Librarian re-checks PubMed, Europe PMC and ClinicalTrials daily, so these counts move. Open each profile to read the summaries and sources.
Frequently asked questions
Is IGF-1 DES (Des(1-3) IGF-1) or IGF-1 LR3 (Long R3 IGF-1) better?
It depends on your goal. IGF-1 DES (Des(1-3) IGF-1) is strongest for muscle; IGF-1 LR3 (Long R3 IGF-1) for muscle. IGF-1 DES (Des(1-3) IGF-1) has more indexed studies (22). See the goal-by-goal breakdown above.
Is IGF-1 DES (Des(1-3) IGF-1) or IGF-1 LR3 (Long R3 IGF-1) better for weight loss?
IGF-1 LR3 (Long R3 IGF-1) shows the stronger metabolic & appetite profile (3.0/5) in the AI-assigned effect profile — though weight-loss outcomes depend on the individual and the evidence base.
Is IGF-1 DES (Des(1-3) IGF-1) or IGF-1 LR3 (Long R3 IGF-1) better for muscle?
Both land close on the muscle & body-composition axis.
Which has more research, IGF-1 DES (Des(1-3) IGF-1) or IGF-1 LR3 (Long R3 IGF-1)?
IGF-1 DES (Des(1-3) IGF-1) has 22 approved studies indexed (Human clinical); IGF-1 LR3 (Long R3 IGF-1) has 14 (Human evidence). Higher counts mean more to read, not proven superiority.
Can you stack IGF-1 DES (Des(1-3) IGF-1) and IGF-1 LR3 (Long R3 IGF-1)?
Some users combine peptides, but there's little controlled data on this specific pairing, and interactions aren't well characterized. We don't publish stacking protocols for compounds that aren't FDA-approved. Discuss any combination with a qualified clinician.
What are the side effects of IGF-1 DES (Des(1-3) IGF-1) vs IGF-1 LR3 (Long R3 IGF-1)?
IGF-1 DES (Des(1-3) IGF-1): no community-reported effects logged yet. IGF-1 LR3 (Long R3 IGF-1): none logged yet. These are anonymous reports, not incidence rates — see each profile.
Is IGF-1 DES (Des(1-3) IGF-1) or IGF-1 LR3 (Long R3 IGF-1) FDA-approved?
IGF-1 DES (Des(1-3) IGF-1) is a research-use compound and is not FDA-approved. IGF-1 LR3 (Long R3 IGF-1) is not FDA-approved. Research-use status is not a legal clearance to compound or use in humans.
Is IGF-1 LR3 (Long R3 IGF-1) better than IGF-1 DES (Des(1-3) IGF-1)?
For muscle, IGF-1 LR3 (Long R3 IGF-1) has the edge; for muscle, IGF-1 DES (Des(1-3) IGF-1) does. Neither is universally "better" — it's goal-dependent, and both should be weighed against their evidence base above.
Comparing related peptides
Regulatory & legal status
IGF-1 DES (Des(1-3) IGF-1) and IGF-1 LR3 (Long R3 IGF-1) are research-use compounds and are not FDA-approved for human use. FDA approval and compounding rules for peptides change frequently, and research-use status is not a legal clearance for human use. The FDA does not review compounded drugs for safety, effectiveness, or quality. Verify current status with primary sources before acting. Last reviewed September 21, 2026.